Back to News

FDA Confirms U.S. IV Saline Shortage Resolved — A Critical Recovery for Surgical Operations

By Laura Mitchell|
FDA Confirms U.S. IV Saline Shortage Resolved — A Critical Recovery for Surgical Operations
FDA Confirms U.S. IV Saline Shortage Resolved — A Critical Recovery for Surgical Operations

On August 8, 2025, the U.S. Food and Drug Administration (FDA) officially declared the national shortage of intravenous (IV) saline solutions resolved. This supply disruption, which began in late 2024, had forced hospitals and ambulatory surgery centers (ASCs) to delay elective surgeries, adopt conservation measures, and source fluids from non-traditional suppliers.

The shortage’s end restores stability to one of the most essential consumables in surgical care—sodium chloride 0.9% injection—and offers a moment to re-examine how the U.S. can better protect critical medical supply chains.

The crisis began after Hurricane Helene struck the Southeastern U.S. in September 2024, severely damaging Baxter International’s manufacturing facility in Marion, North Carolina. This plant had been producing an estimated 60% of the nation’s IV saline supply, approximately 1.5 million units daily. With production halted, hospitals reported sharp shortages by October 2024, prompting the FDA to add sodium chloride IV solutions to its official shortage list.

The FDA’s August 2025 press release confirms that coordinated efforts—including accelerated repair of Baxter’s facility, increased production from Fresenius Kabi and B. Braun Medical, and importation from approved foreign manufacturers—returned national supply levels to pre-crisis norms by May. By August, inventories were stable enough to formally close the shortage listing.

Why It Matters to the Surgical Market

Image 5

1. Restored Operating Room Throughput

IV saline is indispensable in surgery—used for preoperative hydration, drug dilution, and irrigation of surgical fields. The shortage caused cascading delays, as elective cases were postponed to conserve stock for emergencies. Resolution means surgical schedules can return to normal without rationing protocols.

2. Reduced Procurement Volatility

Supply chain managers spent months chasing scarce stock through spot buys and emergency shipments. With inventory stability restored, hospitals can resume standard purchase agreements and inventory rotation.

3. Risk Awareness for Critical Consumables

The shortage exposed the dangers of over-reliance on a single manufacturing site for high-volume, low-margin items. Even as the crisis resolves, surgical supply teams are urged to establish dual-source agreements for Tier-1 consumables.

4. Potential Price Stabilization

Scarcity had driven IV saline costs higher, both from supplier surcharges and freight premiums. Restored production capacity could normalize pricing by Q4 2025, relieving budgetary pressure on perioperative services.

Hospitals and ASCs

Facilities nationwide—especially those in hurricane-affected regions—were hit hardest. They can now resume elective surgeries without contingency hydration protocols.

Surgical Teams

Surgeons, anesthesiologists, and perioperative nurses return to normal saline-based workflows, which reduces procedure time and mitigates infection control risks associated with substitutes.

Patients

Postponed orthopedic, cardiovascular, and laparoscopic procedures can be rescheduled without uncertainty over fluid availability.

Manufacturers and Distributors

Baxter, Fresenius, and B. Braun are now under pressure to maintain redundancy in their production networks. Distributors must improve demand-forecasting models to detect early warning signs of shortages.

Lessons from the Shortage

Image 23

In December 2024, Becker’s Hospital Review detailed how health systems adapted to the saline shortage—ranging from IV conservation protocols to the use of alternative hydration fluids. These measures kept surgical operations running at reduced capacity, but at the cost of efficiency and workflow familiarity.

The shortage revealed three systemic weaknesses in the U.S. surgical supply chain:

• Geographic concentration of production

• Limited onshore redundancy for high-demand consumables

• Slow detection of disruption impact in the hospital setting

Addressing these requires investment in distributed manufacturing, expanded federal stockpiles for consumables, and stronger real-time inventory monitoring systems.

Regulatory Role

The FDA played an active facilitation role during the crisis, as outlined in its August 2025 statement. The agency:

• Worked with domestic producers to expedite production scale-ups

• Temporarily relaxed certain import restrictions

• Monitored hospital inventory levels to prioritize distribution to the most affected regions

This flexible approach helped resolve the shortage within months—a pace considered rapid for a disruption of this magnitude.

“The saline shortage was a wake-up call for the surgical supply community. We can’t afford to let a single plant carry more than half of national demand for an essential medical consumable. The speed of this recovery was impressive, but the next test may not be so forgiving.”

- Surgical Market Watcher Team

Audit Stock Levels: Ensure current saline inventories meet pre-shortage surgical demand plus a strategic buffer.

Diversify Supplier Contracts: Implement dual-vendor agreements for critical consumables.

Monitor FDA Shortage Updates: Track changes to shortage lists and import authorizations for early warning.

Sources